For more information, or to register for this event, visit A Rare Look into New Guidances: The Future State of Orphan Drug Development.

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

The "Pharmaceutical Review Designations: Trends and Industry Insights" report has been added to ResearchAndMarkets.com's offering.This report investigates review designations in the pharmaceutical ...

The global market for frontotemporal disorders treatment, valued at USD 343.8 million in 2022, is projected to experience steady year-on-year growth, with an anticipated Compound Annual Growth Rate ...

Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...

The company's India business, comprising both formulations and consumer wellness divisions, contributed 38 per cent of ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

Zydus Lifesciences Limited reports 30% profit increase, driven by US formulations business, with strong financial position ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse ...

Exo-Top was established under the jurisdiction of the State of Nevada. Basing Exo-Top in the U.S. offers key advantages, including proximity to strategic partners, access to a robust biopharma ...

San Francisco, California Wednesday, February 5, 2025, 16:00 Hrs [IST] ...

ASX pops with miners, Pinnacle smashes records, and SEC eases up on crypto while Trump gives a nod to talks ... Read More The ...